Company intelligence
Mirum Pharmaceuticals, Inc.
Delivering High Impact Medicines for Rare Disease
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com.
Verified activity
Signals from Mirum Pharmaceuticals, Inc.
8 published signals
People
Mirum Pharmaceuticals, Inc. is hiring an Associate Director, Marketing to lead its hepatitis delta (HDV) diagnostics and patient-finding strategy.
Reported by Michelle Melka
Presence & Recognition
Mirum Pharmaceuticals, Inc. participated in the 2026 International FOP Association Drug Development Forum in Toronto to exchange ideas and perspectives with the international fibrodysplasia ossificans progressiva (FOP) community.
Reported by Mirum Pharmaceuticals, Inc.
Presence & Recognition
Mirum Pharmaceuticals, Inc. is hosting a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, at 10:45 a.m. ET.
Reported by Mirum Pharmaceuticals, Inc.
Presence & Recognition
Mirum Pharmaceuticals, Inc. is hosting a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, at 9:00 a.m. ET.
Reported by Mirum Pharmaceuticals, Inc.
Presence & Recognition
Mirum Pharmaceuticals, Inc. is hosting a fireside chat at the Citi’s 2026 Biopharma Back-to-School Conference on Thursday, September 10, at 10:00 a.m. ET.
Reported by Mirum Pharmaceuticals, Inc.
Presence & Recognition
Mirum Pharmaceuticals, Inc. is hosting a fireside chat at the Cantor 2026 Global Healthcare Conference on Wednesday, September 9, at 10:55 a.m. ET.
Reported by Mirum Pharmaceuticals, Inc.
Presence & Recognition
Mirum Pharmaceuticals, Inc. is hosting a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15.
Reported by Mirum Pharmaceuticals, Inc.
Presence & Recognition
Mirum Pharmaceuticals, Inc. was ranked 17th among medium-sized workplaces and 1st among biotechs recognized by Fortune and Great Place To Work.
Reported by Mirum Pharmaceuticals, Inc.